Peptides for Gastroparesis: Emerging Treatment Options

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide therapies such as ghrelin and motilin receptor agonists show promise in improving gastric emptying in gastroparesis patients. Clinical responses vary, and dosing protocols typically start with 3mcg/kg ghrelin or 50mcg erythromycin derivatives twice daily.

Gastroparesis and Its Clinical Challenge

Gastroparesis affects approximately 4% of the population, characterized by delayed gastric emptying without mechanical obstruction. Patients present with nausea, early satiety, bloating, and weight loss. Standard treatments, including prokinetic agents like metoclopramide (10mg TID), often have limited efficacy or unacceptable side effects, prompting exploration of peptide-based therapies.

Peptides That Enhance Gastric Motility

Two peptides have gained attention: ghrelin and motilin receptor agonists. Ghrelin, a 28-amino acid peptide primarily secreted by the stomach, stimulates appetite and gastric motility via the growth hormone secretagogue receptor (GHS-R1a). Motilin, a 22-amino acid peptide from the small intestine, coordinates migrating motor complexes during fasting.

Ghrelin Agonists

In a 2017 randomized controlled trial by Tack et al., intravenous ghrelin at doses of 3mcg/kg twice daily improved gastric emptying by 30% over placebo in idiopathic gastroparesis patients. However, oral ghrelin agonists have variable bioavailability and inconsistent clinical results. Relamorelin, a synthetic ghrelin receptor agonist dosed at 100mcg subcutaneously twice daily, demonstrated a 40% improvement in gastric emptying and symptom scores over 12 weeks in diabetic gastroparesis (Camilleri et al., 2019).

Mechanistically, ghrelin enhances antral contractions and coordinates fundic relaxation, improving gastric accommodation. Some patients experience transient hyperglycemia due to growth hormone stimulation, requiring close glucose monitoring.

Motilin Receptor Agonists

Erythromycin, a macrolide antibiotic, acts as a motilin receptor agonist. Low-dose erythromycin (50mg orally twice daily) accelerates gastric emptying but often causes tachyphylaxis within weeks. Mitemcinal, a non-antibiotic motilin agonist, showed promise in phase II trials but failed to achieve significant symptom relief long-term.

Motilin agonists promote phase III migrating motor complexes, improving interdigestive motility. However, their prokinetic effect is short-lived, and tachyphylaxis limits chronic use. Combination therapy with ghrelin agonists may overcome some limitations but requires further study.

Comparisons and Clinical Nuances

Compared to traditional prokinetics like metoclopramide or domperidone, peptides offer a targeted mechanism with potentially fewer neurological side effects. Yet, peptides require parenteral administration or suffer from poor oral bioavailability. Ghrelin agonists also carry a risk of stimulating appetite excessively, which may be undesirable in overweight diabetics, whereas motilin agonists do not affect appetite.

Patient selection is crucial. Diabetic gastroparesis responds better to ghrelin agonists, possibly due to autonomic neuropathy affecting ghrelin pathways (Camilleri et al., 2019). Idiopathic gastroparesis shows variable responses. Coexisting gastroparesis with delayed gastric accommodation may benefit more from ghrelin agonists due to their fundic relaxation effects.

Practical Dosing and Monitoring

Initiate ghrelin receptor agonists at 100mcg subcutaneously twice daily, titrating based on symptom relief and gastric emptying studies (scintigraphy or breath tests). Monitor blood glucose closely if diabetic. For motilin agonists, erythromycin 50mg orally twice daily can be trialed short-term, but anticipate tachyphylaxis by 4-6 weeks.

Peptide therapy should be part of a multidisciplinary approach including dietary modification (small frequent meals, low fat), glycemic control, and symptom management. Long-term safety data are limited; therefore, regular clinical follow-up and symptom reassessment every 3 months are recommended.

Future Directions

Research continues on oral ghrelin agonists with improved bioavailability and motilin receptor agonists without tachyphylaxis. Combination peptide therapy targeting multiple motility pathways could enhance outcomes. Biomarkers predicting peptide response may optimize patient selection.

Clinical Takeaway

Consider ghrelin receptor agonists like relamorelin at 100mcg SC twice daily for diabetic gastroparesis patients with poor response to traditional prokinetics. Use motilin receptor agonists such as low-dose erythromycin as short-term adjuncts, being mindful of tachyphylaxis. Tailor peptide therapy based on symptom pattern, underlying etiology, and monitor glucose metabolism closely.